According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...
Short-course (3-month) enzalutamide monotherapy in biochemically recurrent prostate cancer (BCR): Preliminary prostate specific membrane antigen tumor volume (PSMA-TV) data. Anatomical location of ...
For years, the treatment of early-stage prostate cancers that haven't spread beyond the organ has often included the removal of nearby lymph nodes in the pelvis. It's done as a precaution and as a ...
WASHINGTON -- Extended pelvic lymph node dissection (ePLND) after radical prostatectomy failed to improve survival in intermediate- and high-risk prostate cancer over standard lymphadenectomy, ...
Removing lymph nodes during cancer surgery has saved countless lives in many tumour types. Yet recent research is challenging parts of this long-standing practice. Imagine your body’s immune defences ...
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study We conducted a multicenter, open-label, ...
Increased urinary urgency Frequent nighttime awakenings to urinate A slow or weak urinary flow Blood in the urine or semen As prostate cancer progresses and spreads to other areas of the body, it may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results